Cargando…

Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data

BACKGROUND: Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maroun, Rana, Mitrofan, Laura, Benjamin, Laure, Nachbaur, Gaelle, Maunoury, Franck, Le Jeunne, Philippe, Durand-Zaleski, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822611/ https://www.ncbi.nlm.nih.gov/pubmed/29466966 http://dx.doi.org/10.1186/s12885-018-4117-z

Ejemplares similares

In-Hospital Economic Burden of Metastatic Renal Cell Carcinoma in France in the Era of Targeted Therapies: Analysis of the French National Hospital Database from 2008 to 2013
por: Maroun, Rana, et al.
Publicado: (2016)

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France
por: Maunoury, Franck, et al.
Publicado: (2018)

A Real-World Cost-Effectiveness Study Evaluating Imaging Strategies for the Diagnostic Workup of Renal Colic in the Emergency Department
por: Kepka, Sabrina, et al.
Publicado: (2023)

Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
por: Buda-Nowak, Anna, et al.
Publicado: (2017)

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
por: Courtinard, Coralie, et al.
Publicado: (2023)

Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
por: Kucharz, Jakub, et al.
Publicado: (2016)

Chromothripsis and progression-free survival in metastatic colorectal cancer
por: Skuja, Elina, et al.
Publicado: (2017)

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer
por: Fu, Fulbert, et al.
Publicado: (2022)

Poor Survival in Rheumatoid Arthritis Associated with Bronchiectasis: A Family-Based Cohort Study
por: Puéchal, Xavier, et al.
Publicado: (2014)

Predictors of Progression-Free Survival and Overall Survival in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Single-Center Experience
por: Barua, Sasanka Kumar, et al.
Publicado: (2019)

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
por: Castro, Daniela, et al.
Publicado: (2023)

Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases
por: Cadier, Benjamin, et al.
Publicado: (2016)

The association between renal sinus fat area and the progression-free survival in Chinese non-metastatic clear-cell renal cell carcinoma patients
por: Huang, Haichao, et al.
Publicado: (2017)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus
por: Satoh, Tendo, et al.
Publicado: (2017)

Persisting Reversed Clock Syndrome
por: Orssaud, Christophe, et al.
Publicado: (2005)

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2
por: Clark, Joseph I, et al.
Publicado: (2021)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Interpreting overall survival results when progression-free survival benefits exist in today’s oncology landscape: a metastatic renal cell carcinoma case study
por: Tang, Yiyun, et al.
Publicado: (2014)

Experience with Renal Autotransplantation: Typical and Atypical Indications
por: Bourgi, Ali, et al.
Publicado: (2018)

Differential expression of cyclooxygenase-2 in metastatic melanoma affects progression free survival
por: Panza, Elisabetta, et al.
Publicado: (2016)

Progression-free survival and quality of life in metastatic breast cancer: The patient perspective
por: Mertz, Shirley, et al.
Publicado: (2022)

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
por: Peters, Inga, et al.
Publicado: (2014)

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
por: Farnebo, Jacob, et al.
Publicado: (2014)

Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
por: Jonker, D J, et al.
Publicado: (2000)

Prevalence and cost of sickle cell disease in France: real-world analysis using data from the Echantillon Généraliste des Bénéficiaires
por: Beillat, Maud, et al.
Publicado: (2023)

Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients
por: Conry, Robert M., et al.
Publicado: (2016)

Metabolic Parameters as Predictors for Progression Free and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Nemeth, Zsuzsanna, et al.
Publicado: (2020)

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
por: Forsythe, Anna, et al.
Publicado: (2018)

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2021)

Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review
por: Arlegui, Hugo, et al.
Publicado: (2020)

The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma
por: Swallow, Elyse, et al.
Publicado: (2018)

Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis
por: Chen, Qitong, et al.
Publicado: (2020)

Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands
por: van Laar, S.A., et al.
Publicado: (2022)

Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma
por: Lacedonia, Donato, et al.
Publicado: (2021)

Comparison of two data collection processes in clinical studies: electronic and paper case report forms
por: Le Jeannic, Anaïs, et al.
Publicado: (2014)

Implementing Technologies: Assessment of Telemedicine Experiments in the Paris Region: Reasons for Success or Failure of the Evaluations and of the Deployment of the Projects
por: Le Bras, Alicia, et al.
Publicado: (2023)

Changes in therapy and survival of metastatic renal cell carcinoma in Estonia
por: Jürgens, Hannes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i2jr9pam4ta82k6k7vtb4763jk